GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OSTX
OS Therapies is a biotech company developing drugs to treat osteosarcoma, a rare type of bone cancer. Its stock price is a speculative bet on success in this complex area, where there is a significant unmet need.
Share prices of companies in the market segment - Cancer cure
OS Therapies is developing new treatments for osteosarcoma, an aggressive bone cancer that primarily affects children and adolescents, using immunotherapy approaches. We've classified it in the "Cancer Cure" segment. The chart below shows the overall dynamics in the rare cancer treatment sector, where the need for new drugs is particularly high.
Broad Market Index - GURU.Markets
OS Therapies is a biopharmaceutical company developing drugs to treat osteosarcoma and other cancers. Its focus on orphan oncologies makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how OS Therapies compares to it.
Change in the price of a company, segment, and market as a whole per day
OSTX - Daily change in the company's share price OSTX
OS Therapies Incorporated's daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the stock's sensitivity to news about its osteosarcoma treatment clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer cure
OS Therapies Incorporated's daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the stock's sensitivity to news about its osteosarcoma treatment clinical trials, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
OS Therapies Incorporated is a biotechnology company focused on developing treatments for osteosarcoma, a rare type of bone cancer. The company's shares are highly sensitive to clinical trial results. Their dynamics, filled with the hopes of patients and investors, contribute to the overall market momentum in a high-risk and socially significant way.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OSTX
OS Therapies Incorporated's year-over-year performance is a story about developing a therapy for osteosarcoma, a rare type of bone cancer. Its 12-month market cap is entirely dependent on clinical trial data. The success of its immunotherapy-based approach could offer new hope for patients with this devastating disease.
Annual dynamics of market capitalization of the market segment - Cancer cure
OS Therapies, a private biotech company, develops drugs to treat cancer. Its growth depends on success in clinical trials. Its valuation will reflect investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OS Therapies is a very small and highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by news of trials and investor confidence in the potential of its developments, making it a high-risk bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OSTX
OS Therapies is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its lead therapy for osteosarcoma triggers an immediate and strong investor reaction, typical of biotech.
Monthly dynamics of market capitalization of the market segment - Cancer cure
OS Therapies develops therapies for the treatment of osteosarcoma, a rare type of bone cancer, primarily in children. This is a socially significant but narrow niche. The company's success depends entirely on the results of clinical trials. The oncology sector's schedule reflects the general interest in new treatments, but OS Therapies prioritizes support for orphan diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
OS Therapies develops a therapy for the treatment of osteosarcoma, a rare type of bone cancer. The company's shares, focused on orphan diseases, live in a world of their own. Their price is determined by progress in clinical trials and FDA decisions. There is virtually no connection to overall market trends, as the chart demonstrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OSTX
OS Therapies, a biopharmaceutical company developing therapies for rare cancers, particularly osteosarcoma, is experiencing high volatility. Weekly stock performance is driven by news of clinical trials, reflecting patient and investor hopes for a breakthrough.
Weekly dynamics of market capitalization of the market segment - Cancer cure
OS Therapies develops a treatment for osteosarcoma, a rare type of bone cancer. Focusing on orphan diseases can be very profitable. The chart will help separate its own news-driven dynamics from the general fluctuations in the oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OS Therapies is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that OSTX's performance is largely uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
OSTX - Market capitalization of the company OSTX
OS Therapies' stock price is a financial bet on the fight against bone cancer (osteosarcoma). The company's market cap reflects the hopes for its drug, designed to treat this rare and fatal disease in children and adolescents. Its dynamics are a barometer of progress in clinical trials, where the lives of young patients are at stake.
OSTX - Share of the company's market capitalization OSTX within the market segment - Cancer cure
OS Therapies' market share in oncology is driven by a new approach to treating osteosarcoma, a bone cancer. Its market share reflects the potential of its therapy, developed to prevent metastases in children and young adults, a critical challenge in this field.
Market capitalization of the market segment - Cancer cure
OS Therapies develops a treatment for osteosarcoma, a rare type of bone cancer. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the importance of focusing on orphan diseases, where the need for new drugs is particularly high.
Market capitalization of all companies included in a broad market index - GURU.Markets
OS Therapies develops a treatment for osteosarcoma, a rare type of bone cancer. Its market capitalization represents hope for patients with this disease. The chart below shows the economic weight of companies focused on treating orphan cancers.
Book value capitalization of the company, segment and market as a whole
OSTX - Book value capitalization of the company OSTX
OS Therapies is a clinical-stage biopharmaceutical company. Its book value represents its equity. The chart below shows its financial resources for osteosarcoma drug development. This level is an indicator of its ability to fund its research programs.
OSTX - Share of the company's book capitalization OSTX within the market segment - Cancer cure
OS Therapies is a biotech company developing a treatment for bone cancer. Its core capital is intellectual property. The company's physical asset allocation will be minimal, reflecting its focus on research rather than large manufacturing facilities.
Market segment balance sheet capitalization - Cancer cure
OS Therapies is a biotech company whose value is created in laboratories developing drugs for the treatment of osteosarcoma. It's a "lightweight" model based on science. The chart below illustrates the extent to which the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
OS Therapies' balance sheet represents capital focused on developing therapies for osteosarcoma, a rare and aggressive bone cancer in children and adolescents. The book value chart shows the resources devoted to fighting this orphan disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OSTX
OS Therapies is a biotech company developing a treatment for osteosarcoma, a rare bone cancer. It has virtually no assets. Its market capitalization reflects the hope that its drug will help patients for whom treatment options are limited. The chart reflects the high risks and humanitarian significance of its mission.
Market to book capitalization ratio in a market segment - Cancer cure
OS Therapies is a clinical-stage company developing a therapy for osteosarcoma, a rare type of bone cancer. Its valuation is based entirely on the success of its drug. The chart demonstrates the significant premium investors are paying for this potential.
Market to book capitalization ratio for the market as a whole
OS Therapies is developing a therapy for osteosarcoma, a rare type of bone cancer. The chart shows how the market values the company, which is targeting an orphan disease. Its market capitalization is a bet on the success of its clinical trials. Although the market is small, a successful drug could dominate it.
Debts of the company, segment and market as a whole
OSTX - Company debts OSTX
OS Therapies is a clinical-stage biopharmaceutical company focused on treating osteosarcoma and other cancers. Debt instruments are a way for such a company to finance its highly specialized but vital clinical trials, as this chart illustrates.
Market segment debts - Cancer cure
OS Therapies is developing a therapy for osteosarcoma, a rare and aggressive bone cancer. Fighting orphan diseases requires a specific approach. The chart shows the financial standards for the biotech sector, against which the company is raising capital to conduct clinical trials in a small patient population with a high unmet medical need.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OSTX
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive type of bone cancer primarily affecting children. Pharmaceuticals for rare diseases require investment, despite the small market. This chart shows how the company funds its vital but risky research, reflecting its financial vulnerability.
Market segment debt to market segment book capitalization - Cancer cure
Developing drugs for the treatment of bone cancer (osteosarcoma), like OS Therapies, targets a rare and severe disease. This chart illustrates how the biotech sector finances orphan drugs. It allows one to evaluate the financial model of a small company operating in a complex field with a limited market but high need for treatment, compared to the broader pharmaceutical industry.
Debt to book value of all companies in the market
OS Therapies develops treatments for osteosarcoma, a rare bone cancer. Biotech companies targeting orphan diseases require targeted but significant funding. The chart helps put their debt burden into perspective within the broader biopharmaceutical sector.
P/E of the company, segment and market as a whole
P/E - OSTX
This valuation for OS Therapies, a company developing a therapy for osteosarcoma (bone cancer), reflects investor expectations. For a company focused on a rare disease, its value is determined solely by the potential of its drug and its belief in the success of clinical trials.
P/E of the market segment - Cancer cure
This indicator represents the average valuation for the biotech sector in which OS Therapies operates. It reflects the overall level of investor optimism regarding scientific breakthroughs in oncology. The chart provides a benchmark for understanding how the market values developments in the treatment of rare cancers.
P/E of the market as a whole
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive type of bone cancer that primarily affects children and adolescents. It's an area with significant unmet needs. This chart shows biotech sentiment. It helps understand how the market views the company's efforts in this complex area of orphan diseases and whether it believes in its scientific approach.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OSTX
OS Therapies is a biopharmaceutical company developing therapies for the treatment of osteosarcoma, a rare and aggressive type of bone cancer primarily affecting children and adolescents. The company's future depends on the success of its clinical trials. This chart reflects investor expectations regarding its potential in this complex area, where new treatments are urgently needed.
%20P%2FE%20OSTX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OSTX&v=1772588231991 "Chart of the company's future (projected) P/E OSTX")
Future (projected) P/E of the market segment - Cancer cure
OS Therapies is developing a therapy for osteosarcoma, an aggressive bone cancer common in children and adolescents. This is a complex and socially significant area of oncology. The chart reflects expectations for the biotech sector, providing context for assessing how the market views this highly specialized development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772588232019 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
OS Therapies develops targeted therapies for the treatment of osteosarcoma, an aggressive bone cancer primarily found in children and adolescents. This graph of overall expectations demonstrates the market's willingness to fund treatments for rare diseases. Investor optimism and a focus on orphan drugs are essential to attracting funding for research that could save the lives of young patients.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772588232039 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OSTX
OS Therapies is developing a therapy for osteosarcoma, a rare type of bone cancer. This chart shows the financial health of the biotech company, which focuses on orphan diseases. Future profitability depends on the success of clinical trials and approval of its drug, which targets a small but high-need patient population.
Profit of companies in the market segment - Cancer cure
Cosmos Health Inc. is a diversified healthcare holding company, distributing pharmaceuticals and nutraceuticals. Its profitability is the sum of the results of its various businesses. This chart illustrates how diversification within a single broad industry can mitigate risks, but success still depends on performance in each specific segment.
Overall market profit
OS Therapies is a biotech company developing a therapy for osteosarcoma, a rare type of bone cancer. The company is currently in clinical trials. Its mission is to find an effective treatment for a disease that primarily affects children and young adults, where progress has been minimal for decades.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OSTX
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive type of bone cancer, primarily in children and adolescents. The company's revenue outlook for such a highly specialized company depends on the success of its clinical trials. This chart reflects analyst expectations for its orphan oncology developments.
%20profit%20of%20the%20company%20OSTX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OSTX&v=1772588232248 "Graph of future (projected) profit of the company OSTX")
Future (predicted) profit of companies in the market segment - Cancer cure
OS Therapies is developing immunotherapy for the treatment of osteosarcoma, an aggressive bone cancer that primarily affects children and adolescents. It's a niche but crucial area of oncology. This chart shows profitability forecasts for the oncology sector, reflecting the hopes associated with finding new treatments for rare and difficult-to-treat cancers.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772588232274 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
OS Therapies Incorporated is a biopharmaceutical company focused on the treatment of osteosarcoma, a rare type of bone cancer. Its future depends on success in clinical trials. The overall corporate earnings forecasts shown here influence investor risk appetite, which determines funding for orphan drug development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772588232281 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OSTX
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive type of bone cancer that primarily affects children and adolescents. Currently in the clinical stage, it has no commercial revenue. The chart reflects investor hopes that its therapy will improve treatment outcomes for this devastating disease.
P/S market segment - Cancer cure
OS Therapies Incorporated is a clinical-stage biopharmaceutical company developing immunotherapy for the treatment of osteosarcoma, a rare and aggressive type of bone cancer primarily affecting children and adolescents. This chart shows the average valuation for the sector, allowing one to assess the market's perception of the revenue potential of OS Therapies' developments.
P/S of the market as a whole
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive type of bone cancer that primarily affects children and adolescents. The company is in clinical trials. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in orphan oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OSTX
OS Therapies develops drugs to treat osteosarcoma, a rare type of bone cancer. This chart reflects investor confidence in the future success of its developments. The valuation is based on clinical trial expectations and potential revenue from drugs aimed at addressing the unmet need for this disease.
%20P%2FS%20OSTX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OSTX&v=1772588232369 "The graph of the company's future (projected) P/S OSTX")
Future (projected) P/S of the market segment - Cancer cure
OS Therapies is developing Listeria-based immunotherapy for the treatment of osteosarcoma, an aggressive bone cancer that primarily affects children and adolescents. The chart shows how investors estimate OS Therapies' future sales, reflecting the company's hopes for a new treatment for this rare and debilitating disease.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772588232377 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Investor optimism about future earnings hinges on the discovery of new treatments for rare cancers, such as osteosarcoma. OS Therapies is working to develop a treatment for this devastating disease, which primarily affects children and adolescents. Their dedicated work inspires hope in patients and demonstrates that biotechnology is fighting for the survival of every life.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772588232388 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OSTX
OS Therapies is a clinical-stage biotech company focused on developing therapies for the treatment of osteosarcoma, a rare type of bone cancer. The company does not yet have commercial sales revenue. Its financial chart reflects investments in its clinical trials aimed at addressing a complex medical problem in children and adolescents.
Sales of companies in the market segment - Cancer cure
OS Therapies develops immunotherapy drugs for the treatment of osteosarcoma, an aggressive bone cancer that primarily affects children and adolescents. This chart shows total revenue in the targeted oncology sector. It illustrates the importance and complexity of drug development for rare and severe diseases, particularly in pediatric oncology.
Overall market sales
OS Therapies is a clinical-stage biopharmaceutical company developing therapies for osteosarcoma, a rare and aggressive bone cancer. Focused on an orphan disease, its success depends on clinical data and regulatory support. This overall economics has little impact on its operations, which are driven by medical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OSTX
OS Therapies is developing a therapy for the treatment of osteosarcoma, a rare and aggressive type of bone cancer. The company is in the clinical stage, and its future depends on the success of its trials. The chart shows analysts' speculative revenue forecasts, which are a bet on the company's ability to offer an effective treatment for this devastating disease.
%20sales%20of%20the%20company%20OSTX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OSTX&v=1772588232551 "Schedule of future (projected) sales of the company OSTX")
Future (projected) sales of companies in the market segment - Cancer cure
OS Therapies develops drugs to treat osteosarcoma, a rare and aggressive bone cancer that primarily affects children and adolescents. The company aims to address unmet medical needs. This chart displays projected revenue for the entire oncology sector, providing insight into overall expectations for the rare cancer drug market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772588232603 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
OS Therapies is a clinical-stage biopharmaceutical company developing a therapy for osteosarcoma, a rare type of bone cancer. Its future depends entirely on the success of clinical trials. This overall economic activity schedule impacts the availability of funding for orphan disease research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772588232688 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OSTX
OS Therapies is a biotech company developing therapies for osteosarcoma, a rare type of bone cancer. This metric reflects the financial aspect of its mission, demonstrating the amount of investment in clinical trials required to bring a new drug to market and help patients with this devastating disease.
Market segment marginality - Cancer cure
OS Therapies is a clinical-stage biopharmaceutical company developing therapies for osteosarcoma and other cancers. Profitability is a future goal. This metric reflects its operational structure and the level of investment in developing treatments for rare oncologies.
Market marginality as a whole
OS Therapies is developing a treatment for osteosarcoma, a rare and aggressive type of bone cancer, primarily in children. Their approach is based on immunotherapy. Currently in the clinical stage, their future depends on the success of their trials. This overall profitability schedule does not affect their operations, which are motivated by urgent medical need.
Employees in the company, segment and market as a whole
Number of employees in the company OSTX
OS Therapies is a biopharmaceutical company focused on developing therapies for osteosarcoma, a rare type of bone cancer. While in the clinical stage, it has a very small, focused team. This chart shows the dynamics of this compact team leading development in this complex area of orphan diseases.
Share of the company's employees OSTX within the market segment - Cancer cure
OS Therapies develops immunotherapy for the treatment of osteosarcoma, a rare bone cancer. This chart shows the concentration of unique oncologists and immunologists. This share of these specialists reflects its focused mission to create new treatments for patients with few other options.
Number of employees in the market segment - Cancer cure
OS Therapies Incorporated is a clinical-stage biopharmaceutical company developing therapies for the treatment of osteosarcoma, a rare type of bone cancer. This chart shows its overall occupancy in the cancer treatment sector. It illustrates the company's focus on orphan diseases for which there is a critical shortage of effective treatments.
Number of employees in the market as a whole
OS Therapies is developing a treatment for osteosarcoma, a rare and aggressive type of bone cancer that primarily affects children and adolescents. This is a socially significant cause. This graph illustrates the labor market, where even small biotech companies working on orphan diseases make a significant contribution by attracting top specialists to save lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OSTX (OSTX)
OS Therapies Incorporated is a biopharmaceutical company developing a treatment for osteosarcoma, a rare type of bone cancer. This chart is a prime example of biotech. The very high market capitalization per employee suggests that the market is evaluating the drug's potential for a specific patient group, rather than the operational activities of a small research team.
%20of%20the%20company%20OSTX%20(OSTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OSTX-OSTX&v=1772588233077 "Chart of market capitalization per employee (in thousands of dollars) of the company OSTX (OSTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
OS Therapies develops a therapy for osteosarcoma, a rare type of bone cancer. It's a biotech company focused on orphan diseases. Their valuation is driven by their hopes for success in this complex field. This metric reflects the value the market places on their efforts. A high valuation indicates a bet on a breakthrough in treating this rare cancer.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772588233123 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
OS Therapies Incorporated is a clinical-stage biopharmaceutical company developing a therapy for osteosarcoma, a rare type of bone cancer. Its valuation is contingent on the success of clinical trials. This metric illustrates how investors value companies targeting orphan diseases with high unmet needs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772588233164 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OSTX (OSTX)
OS Therapies (OSTX) is a clinical-stage biotech R&D company focused on cancer treatment, primarily pediatric osteosarcoma. It's pure science. This metric measures their capital burn rate—the net loss (R&D expenses) per employee.
%20Chart%20OSTX%20(OSTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OSTX-OSTX&v=1772588233208 "Company Profit Per Employee (in thousands of dollars) Chart OSTX (OSTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
OS Therapies is a clinical-stage biotech focused on treating rare cancers, particularly osteosarcoma. As with other R&D firms, this timeline is a goal for the future. Currently, all the value is concentrated in their scientific team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772588233219 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
OS Therapies (OSTX) is a clinical-stage biotech company specializing in the treatment of osteosarcoma (bone cancer). This is R&D. This chart shows the typical biotech picture: negative profit per employee, as all resources are invested in clinical trials to obtain approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772588233255 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OSTX (OSTX)
This chart for OS Therapies, a company developing a treatment for osteosarcoma (bone cancer), reflects the clinical trial stage. Future revenue growth per employee depends on the success of its drug targeting this rare and debilitating disease.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OSTX-OSTX&v=1772588233277 "Sales chart per company employee OSTX (OSTX)")
Sales per employee in the market segment - Cancer cure
OS Therapies is a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma (bone cancer). This is R&D for orphan diseases. This metric reflects the average revenue per employee in the segment. It allows us to assess the productivity of their R&D team in this narrow oncology niche.
Sales per employee for the market as a whole
OS Therapies (OSTX) is a clinical-stage biopharmaceutical company focused on cancer treatment, specifically osteosarcoma. Currently, its staff consists entirely of researchers. This metric is critical for OSTX: it's at zero. Future growth will signal the success of their R&D and the receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company OSTX (OSTX)
OS Therapies is a very early-stage biotech company attempting to treat osteosarcoma (bone cancer) in children and animals. It's a very rare disease. This chart reflects investors' bets that its scientific approach won't work and that the tiny market will prevent it from becoming commercially viable, even if it's technically successful.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OSTX-OSTX&v=1772588233406 "Short Shares Chart for the Company OSTX (OSTX)")
Shares shorted by market segment - Cancer cure
OS Therapies (OSTX) is a biopharmaceutical company focused on developing therapies for osteosarcoma (bone cancer), primarily in children. This chart shows the overall short position in the oncology biotech sector. It reflects the high risk and complexity of drug development for rare cancers.
Shares shorted by the overall market
OS Therapies is a cutting-edge biotech company searching for a cure for cancer. This business requires enormous amounts of long-term capital. When panic mounts in the market, as this chart reflects, investors flee risky ventures. The flow of capital needed for clinical trials dries up, jeopardizing the R&D process itself.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OSTX (OSTX)
This oscillator for OS Therapies shows extreme fluctuations in hope and fear. The company is developing treatments for osteosarcoma, a rare and aggressive form of bone cancer. The stakes are high in this sector. Positive data from early-phase trials is causing euphoria among investors, pushing the indicator toward "overheating" (>70). Any hint of research failure leads to panic selling.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OSTX-OSTX&v=1772588233528 "RSI 14 indicator chart for the company's stock OSTX (OSTX)")
RSI 14 Market Segment - Cancer cure
OS Therapies (OSTX) is a biotech company that targets *rare* bone cancer (osteosarcoma). The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether OSTX's growth is due to their R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
OS Therapies (OSTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OSTX (OSTX)
OS Therapies is a biotech company focused on treating osteosarcoma (bone cancer) and other hard-to-treat cancers. This chart shows the speculative average price target from analysts. Their forecast is almost entirely dependent on the estimated chances of clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OSTX-OSTX&v=1772588233561 "A chart showing analyst consensus forecasts for the expected stock price. OSTX (OSTX)")
The difference between the consensus estimate and the actual stock price OSTX (OSTX)
OS Therapies (OSTX) is a biotech company focused on treating osteosarcoma (bone cancer) in children and animals (dogs). This chart is a barometer of their R&D. It measures the vast gap between the speculative price and the consensus target, reflecting the high (but risky) potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OSTX-OSTX&v=1772588233588 "A chart showing the difference between the consensus forecast and the actual stock price. OSTX (OSTX)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
OS Therapies is a clinical-stage biotech company developing Listeria-based immunotherapy for the treatment of osteosarcoma (bone cancer). This chart shows overall expectations for the oncology sector, reflecting experts' confidence in this innovative R&D platform for treating rare cancers.
Analysts' consensus forecast for the overall market share price
OS Therapies is a biotech company developing antibody-based therapies for the treatment of osteosarcoma, a rare and aggressive bone cancer primarily affecting children. This chart shows the overall risk appetite. For OS Therapies, operating in a niche but critically important field, overall market optimism is important for raising capital for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OSTX
OS Therapies is a biotech company attacking a neglected cancer—osteosarcoma (bone cancer in children and adolescents). Their approach (OST-HER2) is an immunotherapy that trains the immune system to attack this specific tumor. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress in this orphan (rare) field.
AKIMA Market Segment Index - Cancer cure
OS Therapies (OSTX) is a clinical-stage biotech focused on the treatment of osteosarcoma (bone cancer) and other solid tumors, often in children. The chart shows the segment average, helping investors assess how the risks and potential of this highly specialized oncology company compare to the sector average.
The AKIM Index for the overall market
OS Therapies is a biotech company focused on treating osteosarcoma (bone cancer) in children and adults. It uses immunotherapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this rare disease company stacks up against broader economic trends.
